---
run_id: halo-evidence-vs-diagnosis-validation-v9-substrate-workflow-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: substrate_workflow
run_number: 2
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 203
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
condition_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
output_file: model-outputs/substrate_workflow-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `substrate_workflow`, run 2 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 203, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence for DraftPath's success is heavily contaminated by "performance-aware attribution" (BK-0048-card-001). The executive team's praise of the product team as "focused" and "disciplined" is a trait narrative emerging *after* a strong quarter, rather than independent evidence of strategic alignment. Furthermore, the financial gains are confounded by temporary bundle pricing and "roadmap pitching," which create a facade of progress that may not disconfirm the risk that the product lacks core utility (BK-0007-card-001).

The Usage Quality Sprint relies on "broad activity metrics" (usage spikes from managers) and "persuasive stories" (re-tagged support tickets), which BK-0007 warns can look like progress while failing to test the critical assumption. The Commercial Cleanroom tests pricing and sales tactics, but not whether the product actually solves the claims problem.

The **Claim File Review** is the only option that provides a "load-bearing diagnosis" (BK-0001-card-001) of the actual challenge. By inspecting whether suggestions are accepted, rewritten, or "impossible to explain," you move from activity metrics to behavioral validation. This will reveal if the product is a genuine workflow accelerator or merely a tool that managers use for oversight while adjusters revert to manual notes.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample exercise that provides no immediate "hard" financial data to the board. In a high-pressure twelve-day window, the CEO may view this as "endless analysis" (BK-0001 misuse risk) that fails to provide the quantitative certainty of a "Cleanroom" or the perceived velocity of a "Usage Sprint."

### Observable Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you discovered that the primary strategic uncertainty was not *product utility* (do adjusters find it useful?), but rather *monetization viability* (will buyers pay for it without bundles/roadmap promises?). If the product is already known to be functionally sound but the pricing model is the only suspected failure point, the Cleanroom becomes the priority.
